2 weeks Ago By Defense World Staff
Bokf Na increased its position in shares of Cencora, Inc. ( NYSE:COR – Free Report ) by 106.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission.
The institutional investor owned 2,200 shares of the company’s stock after purchasing an additional 1,132 shares during the period. Bokf Na’s holdings in Cencora were worth $496,000 as of its most recent SEC filing. Other hedge funds have also recently added to or reduced their stakes in the company.
Kingswood Wealth Advisors LLC purchased a new position in shares of Cencora in the 2nd quarter valued at about $655,000. TD Asset Management Inc acquired a new stake in shares of Cencora during the 1st quarter valued at approximately $95,313,000. LSV Asset Management purchased a new stake in shares of Cencora during the 1st quarter worth approximately $3,579,000.
Cairn Investment Group Inc. acquired a new stake in shares of Cencora in the 1st quarter worth approximately $2,294,000. Finally, Lake Street Advisors Group LLC purchased a new position in Cencora in the 1st quarter valued at approximately $836,000.
Institutional investors and hedge funds own 97.52% of the company’s stock. Analyst Upgrades and Downgrades COR has been the topic of a number of research analyst reports.
JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.
00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Wells Fargo & Company increased their price objective on shares of Cencora from $236.00 to $249.
00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd.
Robert W. Baird lowered their price target on shares of Cencora from $287.00 to $283.
00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Finally, Leerink Partners restated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th.
Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $258.
13. Insider Buying and Selling In related news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.
69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.
12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website . In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction dated Tuesday, August 6th.
The stock was sold at an average price of $242.69, for a total transaction of $357,482.37.
Following the completion of the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink .
Also, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $222.
12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now owns 285,088 shares in the company, valued at $63,323,746.
56. The disclosure for this sale can be found here . Over the last three months, insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799.
Insiders own 15.80% of the company’s stock. Cencora Stock Up 0.
6 % COR stock opened at $241.24 on Tuesday. The company has a 50 day moving average price of $234.
28 and a two-hundred day moving average price of $233.28. The company has a debt-to-equity ratio of 3.
93, a quick ratio of 0.55 and a current ratio of 0.89.
The stock has a market capitalization of $48.12 billion, a P/E ratio of 26.39, a PEG ratio of 1.
55 and a beta of 0.44. Cencora, Inc.
has a one year low of $177.00 and a one year high of $247.66.
Cencora ( NYSE:COR – Get Free Report ) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.
18 by $0.16. The business had revenue of $74.
20 billion during the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a return on equity of 266.
60% and a net margin of 0.65%. The business’s revenue for the quarter was up 10.
8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.92 earnings per share.
As a group, sell-side analysts expect that Cencora, Inc. will post 13.63 EPS for the current year.
Cencora Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a dividend of $0.51 per share.
The ex-dividend date was Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.
85%. Cencora’s payout ratio is currently 22.32%.
Cencora Profile ( Free Report ) Cencora, Inc sources and distributes pharmaceutical products. The company's U.S.
Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. Featured Articles Five stocks we like better than Cencora What is a Dividend King? Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible What is a Dividend Harvesting Strategy and How Can Investors Profit from it? Roblox’s Growth Beyond Kids: Stock Set for Major Moves Profitably Trade Stocks at 52-Week Highs 5 Oversold Stocks to Buy Right Now Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc.
( NYSE:COR – Free Report ). Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter .
.
